Skip to main content
. Author manuscript; available in PMC: 2020 Nov 15.
Published in final edited form as: Brain Res. 2019 Aug 21;1723:146398. doi: 10.1016/j.brainres.2019.146398

Table 1.

Compounds that Modulate the Dopaminergic System. A summary of compounds with varying mechanisms of action to increase or decrease dopaminergic activity. References in the table refer to the specific studies that demonstrate that these drugs change dopamine levels and/or dopamine turnover. As the aging HIV population uses a number of different drugs, many of which impact dopamine but are not always indicated to affect the dopaminergic system, caution should be used in taking them as they may affect the progression of NeuroHIV, depression, and other age-related comorbidities.

Generic Name Brand Names Mechanism Therapeutic Use References
Dopamine Precursors Levodopa Atamet, Duopa, Larodopa, Parcopa, Prolopa, Rytary, Stalevo, Sinemet Dopamine Precursor Parkinsons’ Disease (PD) (Yahr, 1969; Ng, 1970)
L-phenylalanine N/A Dopamine Precursor Dietary Supplement (Milner et al., 1986; Fernstrom and Fernstrom, 2007; Kapatos and Zigmond, 1977)
L-tyrosine N/A Dopamine Precursor Dietary Supplement (Fernstrom and Fernstrom, 2007; Kapatos and Zigmond, 1977; During et al., 1989)
Dopamine Receptor Agonists Amantadine Symmetrel Dopamine Receptor Agonist/Dopamine Reuptake Inhibitor PD, Antiviral (Von Vigtlander and Moore, 1971; Mizoguchi, 1994)
Apomorphine Apokyn Dopamine Receptor Agonist PD (Andén, 1967; de La Fuente-Fernandez, 2001)
Aripiprazole Abilify, Aripipex Dopamine Receptor Agonist# Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Autism (Li, 2004)
Bromocriptine Cycloset, Parlodel, Brotin Dopamine Receptor Agonist PD, Pituitary tumors, Type 2 Diabetes, Hyperprolactinaemia, Neuroleptic malignant syndrome (Brannan, 1993)
Lisuride Proclacam, Revanii, Dopergin Dopamine Receptor Agonist PD, Migraine (Kehr, 1977)
Memantine Axura, Akatinol, Abixa, Memox, Ebixa, Namenda Dopamine Receptor Agonist Alzheimers’ Disease (AD) (Spanagel et al., 1994)
Pramexipole Mirapex, Mirapexin, Sifrol Dopamine Receptor Agonist PD, Restless Leg Syndrome (RLS) (Carter and Müller, 1991)
Piribedil Pronoran, Trivastal Retard, Trastal, Trivastan, Clarium Dopamine Receptor Agonist Parkinsons’ Disease, Elderly dizziness and cognitive deficit, retinal ischemic manifestations (Gil-Loyzaga, 1994; Delbarre, 1995)
Rotigotine Neupro Dopamine Receptor Agonist MDD, PD, RLS, Willis-Ekborn Disease (Kehr, 2007)
Dopamine Receptor Antagonists Amisulpride Solian Dopamine Receptor Antagonist Schizophrenia, Dysthymia (Schoemaker, 1997)
Chlorpromazine Largactil, Thorazine Dopamine Receptor Antagonist ADHD, Bipolar Disorder, Nausea, Schizophrenia, Vomiting (Starke, 1978; Stamford et al., 1986)
Clozapine Clozaril Dopamine Receptor Antagonist Treatment-resistant Schizophrenia (Youngren, 1999; Meltzer, 1989; Drew, 1990)
Domperidone Motilium Dopamine Receptor Antagonist Nausea, vomiting, Gastroprokinetic, Galactagogue (Champion, 1988)
Fluphenazine Prolixin Dopamine Receptor Antagonist Schizophrenia (Bacopoulos et al., 1979; Goosey and Doggett, 1983)
Haloperidol Haldol Dopamine Receptor Antagonist Schizophrenia, Bipolar Disorder, Tourette Syndrome, Nausea, Vomiting, Delerium (Drew, 1990; Gudelsky and Porter, 1980; Bunney and Grace, 1978)
Loxapine Loxitane Dopamine Receptor Antagonist Schizophrenia, Bipolar Disorder (Li et al., 2003)
Metoclopramide Primperan, Reglan Dopamine Receptor Antagonist Nausea, Vomiting, Migraine (Peringer, 1976)
Molindone Moban Dopamine Receptor Antagonist Schizophrenia (McMillen and McDonald, 1983)
Olanzapine Zyprexa Dopamine Receptor Antagonist Schizophrenia, Bipolar Disorder (Zhang, 2000; Li, 1998)
Perphenazine Trilafon Dopamine Receptor Antagonist Schizophrenia, Bipolar Disorder, Depression (Mjörndal and Persson, 1990)
Pimozide Orap Dopamine Receptor Antagonist Schizophrenia, Tourette Syndrome (Matsuo, 2010; Parsons et al., 1993)
Prochlorperazine Compro Dopamine Receptor Antagonist Schizophrenia, Nausea, Migraine, Anxiety (Goosey and Doggett, 1983)
Quetiapine Seroquel Dopamine Receptor Antagonist Schizophrenia, Bipolar Disorder, Depression, Sleep Aid (Pira et al., 2004; Silverstone et al., 2012)
Risperidone Risperdal Dopamine Receptor Antagonist Schizophrenia, Bipolar Disorder, Autism (Hertel, 1996; Huang, 2006)
Sulpiride* Dogmatil Dopamine Receptor Antagonist Schizophrenia, Depression (Andersen and Gazzara, 1996)
Thiothixene Navane Dopamine Receptor Antagonist Schizophrenia, Bipolar Disorder (Bjerkenstedt, (1970), 1977)
Trifluoperazine Stelazine Dopamine Receptor Antagonist Schizophrenia, Generalized Anxiety Disorder (GAD) (Goosey and Doggett, 1983)
Ziprasidone Geodon Dopamine Receptor Antagonist Schizophrenia, Bipolar Disorder (Li et al., 2003)
Dopamine Reuptake Inhibitors Armodafanil Nuvigil, Acronite Dopamine Reuptake Inhibitor Sleep Disorders (Loland, 2012)
Benzatropin Cogentin Dopamine Reuptake Inhibitor PD, Dystonia (Goodale and Moore, 1975)
Bupropion Elontril, Wellbutrin, Zyban Dopamine Reuptake Inhibitor Depression, Smoking Cessation, ADHD (Ascher, 1995; Nomikos, 1992)
Dexmethylphenidate Attenade, Focalin Dopamine Reuptake Inhibitor ADHD (Volkow, 2001)
Diphenylpyraline Allergen, Arbid, Belfene, Diafen, Hispril, Histyn, Lergobine, Lyssipol, Mepiben, Neargal Dopamine Reuptake Inhibitor Allergies, PD (Oleson, 2012)
Esketamine Ketanest, Spravato Dopamine Reuptake Inhibitor Anesthesia, Treatment-resistant depression (Hashimoto, 2017)
Methylphenidate Methylin, Concerta, Medikinet, Ritalin, Equasym XL, Metadate, Quillivant XR Dopamine Reuptake Inhibitor ADHD (Heal, 2008)
Modafanil Alertec, Modavigil, Modiodal, Provigil, Modalert Dopamine Reuptake Inhibitor Sleep Disorders (Ferraro, 1996)
Nefazdone Serzone, Dutonin, Nefadar Dopamine Reuptake Inhibitor MDD (Olausson, 1998; Dremencov, 2005)
Nomifensine Merital, Alival Dopamine Reuptake Inhibitor Depression, Anxiety Disorders (Karoum, 1994)
Sertraline Zoloft Weak Dopamine Reuptake Inhibitor MDD, Anxiety Disorders, OCD (Kitaichi, 2010)
Tripelennamine Pyrbenzamine Weak Dopamine Reuptake Inhibitor Allergies (San-Martin-Clark, 1996; Oishi, 1994)
Venlafaxine Effexor, Lanvexin, Trevilor Weak Dopamine Reuptake Inhibitor MDD, Anxiety Disorders (Czubak, 2010)
Monoamine Oxidase Inhibitors Phenelzine Nardil, Nardelzine Non-Selective MAO-I MDD, Anxiety Disorders (Juorio et al., 1986)
Rasagiline Azilect Selective MAO-B Inhibitor PD (Finberg, 1998)
Selegiline Anipryl, Emsam, Deprenyl, Eldepryl, Zelapar, Selgene Selective MAO-B Inhibitor PD, MDD, ADHD (Kitaichi, 2013)
Tranylcypromine Parnate, Jatrosom Non-Selective MAO-I MDD, Mood Disorders, Anxiety Disorders (Shioda, 2004; Ainsworth, 1998)
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors Reserpine Serpalan, Serpasil VMAT2 Inhibitor High Blood Pressure (Elverfors and Nissbrandt, 1991; Okada, 1993)
Tetrabenazine Nitoman, Xenazine VMAT2 Inhibitor Huntington’s Disease, Tardive Dyskinesia, Tourette Syndrome, Hemiballismus (Owesson-White, 2012)
Other Drugs with Dopaminergic Mechanisms Agomelatine* Melitor, Thymanax, Valdoxan Dopamine Releasing Agent Depression (Millan, 2003)
Buspirone Buspar, Buspar Dividose, Vanspar Dopamine Releasing Agent Anxiety Disorders (McMillen and McDonald, 1983; Silverstone et al, 2012; Sakaue, 2000)
Clomipramine Anafranil, Clofranil Weak Dopamine Reuptake Inhibitor/Weak Dopamine Receptor Agonist Depression, OCD, Anxiety Disorders, Other Psychiatric Disorders (Ichikawa and Meltzer, 1995)
Desipramine Norpramin, Pertofrane Dopamine Releasing Agent Depression (Dremencov, 2005)
Disulfiram Antabuse, Antabus Prevents Dopamine Breakdown Cocaine Dependence, Cancer, Alcoholism (Devoto, 2012)
Donepezil Aricept Dopamine Releasing Agent AD (Zhang et al., 2004)
Entacapone Comtan Catechol-O-Methyl Transferase Inhibtor PD (Gerlach, 2004)
Fluoxetine Prozac, Sarafem Dopamine Releasing Agent MDD, OCD, Bulimia, Panic Disorder, Premenstrual Dysphoric Disorder (Zhang, 2000; Sakaue, 2000; Ichikawa and Meltzer, 1995)
Folate N/A Increases Dopamine Turnover Dietary Supplement, Depression (Miller, 2008)
Galantamine Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine Dopamine Releasing Agent AD (Schilstrom, 2007)
Imipramine Tofranil Weak Dopamine Receptor Antagonist Depression (Ichikawa and Meltzer, 1995)
L-methylfolate N/A Increases Dopamine Turnover Dietary Supplement, Depression (Miller, 2008)
Lisdexamfetamine Vyvanse Dopamine Releasing Agent ADHD, Binge eating disorder (Rowley, 2012)
Metirosine Metyrosine Tyrosine Hydroxylase Inhibitor Hypertension, Headahce, Tachycardia, Constipation, Tremors (Naruse, 2018)
Mirtazapine Remeron Dopamine Releasing Agent Depression (Nakayama et al., 2004)
Moclobemide* Aurorix, Manerix Selective MAO-A Inhibitor Depression, Anxiety Disorders (Da Prada, 1989)
Paroxetine Paxil, Seroxat Dopamine Releasing Agent Depression, OCD, PTSD, Panic Disorder, Generalized Anxiety Disorder, Premenstrual Dysphoric Disorder (Nakayama, 2002)
Pergolide* Permax Dopamine Receptor Agonist PD (Herdon and Nahorski, 1987; Fuller and Snoddy, 1981)
Reboxetine Edronax Dopamine Releasing Agent Depression (Linner, 2001)
S-adenosyl methionine N/A Increases Dopamine Turnover Dietary Supplement, Depression (Miller, 2008; Schalinske and Smazal, 2015)
Tolcapone Tasmar Catechol-O-Methyl Transferase Inhibtor PD (Lapish, 2009; Tunbridge, 2004)
Trimipramine Surmontil, Rhotrimine, Stangyl Weak Dopamine Reuptake Depression (Taylor, 1996)
Drugs of Abuse Alcohol N/A Dopamine Releasing Agent N/A (Bosse and Mathews, 2011; Yan, 1999; Weiss, 1996)
Alpha-Pyrrolidinopentiophenone (PVP) N/A Dopamine Reuptake Inhibitor N/A (Hataoka et al., 2017; Glennon and Young, 2016)
Amphetamine N/A Dopamine Releasing Agent N/A (Moghaddam and Bunney, 1989; Tor-Agbidye et al., 2001)
Cocaine N/A Dopamine Reuptake Inhibitor N/A (Wightman, 2007; Shou, 2006; Phillips, 2003)
Heroin N/A Weak Dopamine Releasing Agent N/A (Hemby, 1995; Smith, 2006)
Ketamine Ketalar Dopamine Reuptake Inhibitor Depression (Kokkinou et al., 2018)
Lysergic Acid Diethylamide (LSD) N/A Dopamine Receptor Agonist N/A (Smith et al., 1975; Antkiewicz-Michaluk et al., 1997)
Methylenedioxymethamphetamine (MDMA) N/A Dopamine Releasing Agent N/A (Baumann et al., 2008; Gudelsky et al., 1994)
Methylenedioxypyrovalerone (MDPV) N/A Dopamine Reuptake Inhibitor N/A (Glennon and Young, 2016; Shekar, 2017)
Methamphetamine N/A Dopamine Releasing Agent N/A (Wilson, 1996; Kita, 2000)
Morphine MorphaBond ER, Arymo ER, Astramorph-PF Dopamine Releasing Agent Pain Reliever (Anagnostakis and Spyraki, 1994; Vander Weele, 2014)
Nicotine N/A Weak Dopamine Releasing Agent N/A (Wing, 2015; Di Chiara, 2000)
Oxycodone Xtampza ER, Oxaydo, Roxicodone, and Oxycontin Dopamine Releasing Agent Pain Reliever (Vander Weele, 2014; Zhang, 2009)
Phencyclidine (PCP) N/A Dopamine Reuptake Inhibitor N/A (Hondo, 1994)
Tetrahydrocannabinol (THC) N/A Dopamine Releasing Agent N/A (Chen, 1993; Pistis, 2002)
*

Not prescribed in the United States.

#

Acts as both a dopamine receptor agonist (presynaptic) and a dopamine receptor antagonist (postsynaptic).